Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
暂无分享,去创建一个
Lawrence C Kuo | Laura Sepp-Lorenzino | Weikang Tao | James Hardwick | Youwei Yan | S. Stirdivant | L. Kuo | S. Munshi | M. Ikuta | Weikang Tao | L. Sepp-Lorenzino | R. Lobell | Stephen C Beck | C. Buser | K. Rickert | V. Dudkin | M. Fraley | K. Arrington | G. Hartman | George D Hartman | Edward J Brnardic | Keith Rickert | Sanjeev K Munshi | Constantine Kreatsoulas | Youwei Yan | Carolyn A Buser | Robert B Lobell | Eileen S Walsh | E. Walsh | Xianzhi Mao | Robert M Garbaccio | Mark E Fraley | Constantine Kreatsoulas | Kelly Hamilton | Xianzhi Mao | Mari Ikuta | Justin T Steen | Kenneth L Arrington | Steven M Stirdivant | Bob A Drakas | Edward S Tasber | Vadim Y Dudkin | R. Garbaccio | Justin T. Steen | K. Hamilton | James Hardwick | Edward S. Tasber | Edward J. Brnardic
[1] Daniel F Ortwine,et al. 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. , 2006, Journal of medicinal chemistry.
[2] P. Furet,et al. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. , 1999, Pharmacology & therapeutics.
[3] Michael Reilly,et al. Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[4] Jiri Bartek,et al. Targeting the checkpoint kinases: chemosensitization versus chemoprotection , 2004, Nature Reviews Cancer.
[5] D. E. Clark. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.
[6] Z. Tao,et al. Chk1 inhibitors for novel cancer treatment. , 2006, Anti-cancer agents in medicinal chemistry.
[7] M. Yin,et al. Targeting Molecular Signals in Chk1 Pathways as a New Approach for Overcoming Drug Resistance , 2004, Cancer and Metastasis Reviews.
[8] Maurizio Recanatini,et al. Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes , 2002, Drug safety.
[9] Z. Rankovic,et al. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.
[10] G Camenisch,et al. Cell permeability as a parameter for lead generation in the protein Tyrosine kinase inhibition field. , 2001, Bioorganic & medicinal chemistry letters.
[11] R. Sridhar,et al. An efficient synthesis of 1-H-pyrazole-4-carboxylic acid esters with vilsmeier reagent under neat conditions , 2004 .
[12] A. Kral,et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .
[13] Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. , 2006, Bioorganic & medicinal chemistry letters.
[14] M. Soufiaoui,et al. Nouvelle voie de synthese d'arylpyrazolo -[4,3-c]-quinoleines via la cycloaddition dipolaire −1,3 , 1989 .
[15] T. Kawabe. G2 checkpoint abrogators as anticancer drugs. , 2004, Molecular cancer therapeutics.
[16] M. Prudhomme. Novel checkpoint 1 inhibitors. , 2006, Recent patents on anti-cancer drug discovery.
[17] B. Pfeiffer,et al. Bis-imide granulatimide analogues as potent Checkpoint 1 kinase inhibitors. , 2007, European journal of pharmacology.
[18] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.